American CryoStem Announces Breakthroughs in the Expansion and Lineage-Specific Differentiations of Adipose-Derived Stem Cell...
April 24 2014 - 9:00AM
American CryoStem Corporation (OTCQB:CRYO), a
leading biotechnology developer and licensor of patented adipose
tissue-based adult stem cell technologies, today announced that its
ACS Laboratory division has completed its quarterly laboratory
R&D program ahead of schedule, yielding new intellectual
property and positive results for expanding and differentiating
adipose-derived stem cells (ADSCs). Breakthroughs in American
CryoStem's proprietary cell culture medium (ACSelerateTM) and
culturing methodology have enabled the Company to accelerate the
robust cellular expansion and rapid differentiation of ADSCs to
adipocytes (fat cells), chondrocytes (cartilage-producing cells)
and osteocytes (bone-producing cells). Working with its patented
media technologies, the Company has been able to accelerate early
adipocyte formation to within 24 to 72 hours; to produce
chondrocyte filaments contracting into early cartilaginous tissue
within 48 to 72 hours; and to form heavily mineralized, trabecular
bone tissue within 11 days -- processes that typically require
several weeks to complete.
Dr. Michael Moeller, Chief Scientist at American CryoStem,
stated, "The development of rapid, efficient and reproducible
methods of differentiating distinct mature cells from adipose
tissue will prove invaluable to the Regenerative Medicine industry.
The ability to quickly grow large numbers of ADSCs from patient
samples and to rapidly differentiate them into distinct lineages
will open the door to multiple therapeutic and regenerative
approaches supported in our ongoing university and corporate
collaborations."
"We are pleased with our laboratory's success in developing and
improving the Company's products for research and therapeutic
applications. This improvement is significant to the industry in
that rapid differentiation of harvested adipose derived stem cells
can reduce the lead time for proper and complete identification of
these cells from weeks to just days," added Anthony Dudzinski,
American CryoStem's COO. Continuing, he noted, "Our goal is to
improve and accelerate the movement of cellular therapies from the
lab to the patient."
About American CryoStem Corporation
A biotechnology pioneer in the fields of Regenerative and
Personalized Medicine, American CryoStem operates a
state-of-the-art, FDA-registered, clinical laboratory dedicated to
processing, bio-banking and development of cellular applications
using autologous adipose (fat) tissue and adipose derived stem
cells (ADSCs). Through its scientific efforts, the Company has
built a strong, strategic portfolio of intellectual property,
patent applications, and proprietary operating processes that form
its core standardized cellular platform. For more information,
please visit www.americancryostem.com and www.acslaboratories.com.
You can also find links to blogs, media coverage and press releases
on our corporate Facebook, Twitter, and LinkedIn profiles.
Forward Looking Statements
This press release may contain forward-looking statements,
including information about management's view of American CryoStem
Corporation's ("the Company") future expectations, plans and
prospects. In particular, when used in the preceding discussion,
the words "believes," "expects," "intends," "plans," "anticipates,"
or "may," and similar conditional expressions are intended to
identify forward-looking statements. Any statements made in
this press release other than those of historical fact, about an
action, event or development, are forward-looking
statements. These statements involve known and unknown risks,
uncertainties and other factors, which may cause the results of the
Company, its subsidiaries and concepts to be materially different
than those expressed or implied in such statements. Unknown or
unpredictable factors also could have material adverse effects on
the Company's future results. The forward-looking statements
included in this press release are made only as of the date
hereof. The Company cannot guarantee future results, levels
of activity, performance or achievements. Accordingly, you
should not place undue reliance on these forward-looking
statements. Finally, the Company undertakes no obligation to
update these statements after the date of this release, except as
required by law, and also takes no obligation to update or correct
information prepared by third parties that are not paid for by
American CryoStem Corporation.
CONTACT: Investor Relations Contact:
American CryoStem Corporation
Office: 732-747-1007
info@americancryostem.com
www.americancryostem.com
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Jul 2024 to Aug 2024
American Cryostem (CE) (USOTC:CRYO)
Historical Stock Chart
From Aug 2023 to Aug 2024